(NASDAQ: BDSX) Biodesix's forecast annual revenue growth rate of 15.36% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 7.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.28%.
Biodesix's revenue in 2026 is $102,939,000.On average, 9 Wall Street analysts forecast BDSX's revenue for 2026 to be $1,204,937,676, with the lowest BDSX revenue forecast at $1,147,961,638, and the highest BDSX revenue forecast at $1,253,050,774. On average, 9 Wall Street analysts forecast BDSX's revenue for 2027 to be $1,448,879,524, with the lowest BDSX revenue forecast at $1,370,062,672, and the highest BDSX revenue forecast at $1,562,093,020.
In 2028, BDSX is forecast to generate $1,681,004,120 in revenue, with the lowest revenue forecast at $1,592,374,729 and the highest revenue forecast at $1,757,077,681.